OraSure Technologies Inc. has announced a significant merger agreement with Syntron Bioresearch, Inc. and True Diagnostics, Inc., which will see both companies become wholly-owned subsidiaries of OraSure. The total purchase price for this acquisition is set at $13 million in cash, subject to adjustments for transaction costs and working capital. This strategic move is expected to close within the fourth quarter of 2026, pending customary conditions.
The merger is a pivotal moment for OraSure Technologies, a company known for its innovative solutions in the surgical and medical instruments and apparatus sector. By integrating Syntron and True Diagnostics, OraSure aims to enhance its product offerings and market reach, positioning itself as a more formidable player in the industry.
Background
Founded in Bethlehem, Pennsylvania, OraSure Technologies Inc. operates under the SIC code 3841, which covers Surgical & Medical Instruments & Apparatus. The company is publicly traded on the Nasdaq under the ticker symbol OSUR. It has been actively involved in developing and manufacturing medical devices and diagnostic products.
Recent filings show that the company has been engaged in various activities, including a 10-Q filing on November 9, 2026, which detailed this merger agreement. The company has also filed a 10-Q/A just days later, indicating ongoing adjustments and updates to its financial reporting.
What the Filing Says
The SEC filing states, "On November 9, 2026, the Company signed a definitive merger agreement... Syntron and True will become wholly-owned subsidiaries of the Company." The filing also outlines that the closing of the transaction is subject to customary conditions and is expected to occur within the fourth quarter of 2026.
Impact
This merger could significantly impact various stakeholders, including employees of both Syntron and True Diagnostics, as well as OraSure's existing workforce. Customers may also see an expanded range of products and services as the companies combine their strengths. Additionally, the merger may influence competitors in the surgical and medical instruments sector, as OraSure enhances its market position.
What's Next
The filing does not specify what happens next beyond the expected closing of the transaction in the fourth quarter of 2026. Investors and market watchers will be keen to see how this merger unfolds and its implications for OraSure's future growth.
Source: SEC Accession Number 0001116463-26-000063
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










